5 Big Biopharmaceutical Stocks That Are Finding Favor
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
Zacks.com on MSN4h
Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?
Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...
Bank of America Securities Remains a Buy on Gilead Sciences (GILD)
In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...
Wells Fargo Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.
Mail & Guardian7h
The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar
In December, the Global Fund and the US President’s Emergency Plan for Aids Relief committed to funding the roll-out of ...
Shaping the future of healthcare analytics: Nidhi Shashikumar's data-driven Impact
With over seven years of experience in data science and analytics, Nidhi has led high-impact projects at leading healthcare ...
Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report released on Tuesday, Marketbeat reports. Oppenheimer currently has an ...
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
Shares of Gilead Sciences Inc. GILD shed 1.08% to $114.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...